Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gynecology & Urology Cancer Metabolic Disorders

BioSante's female sexual dysfunction drug LibiGel fails to satisfy in Phase III

This article was originally published in Scrip

Executive Summary

BioSante Pharmaceuticals' investors were anything but satisfied on 15 December, pushing shares of the company down as low as 79%, after the firm revealed that its female sexual dysfunction drug LibiGel (testosterone gel) failed to show it was any better than placebo in treating hypoactive sexual desire disorder in postmenopausal women in two Phase III trials.

Table

View full table

Topics

Related Companies

Tags:
Gynecology & Urology Cancer Metabolic Disorders
Latest Headlines

Analysis: Novo And Lilly Make Their Money Work

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

China Biotech Podcast: AACR, BIOSECURE European Perspectives

See All
UsernamePublicRestriction

Register

SC015587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By